Business
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
PARIS, June 26, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/c198da48b9fa07a371bc390d50555ab5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2Ut4jkW._Bz36BoEmyyOuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c198da48b9fa07a371bc390d50555ab5","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Upstream phase of LUMEVOQ® manufacturing process successfully transferred","length":73,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions","length":117,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":333,"olType":false},{"type":"text","content":"PARIS, June 26, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc.","length":516,"tagName":"p"},{"type":"text","content":""This outstanding result is a significant milestone in GenSight’s strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory submissions," commented Scott Jeffers, Chief Technical Officer of GenSight Biologics. "Our new partnership is proving to be highly effective, not just in completing the tech transfer process successfully, but also in improving the yield and upgrading the analytical methods used to reinforce control over the safety and quality of each batc...